Selected article for: "advanced EBOV vaccine candidate and vaccine candidate"

Author: Fathi, Anahita; Dahlke, Christine; Addo, Marylyn M.
Title: Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens
  • Document date: 2019_9_5
  • ID: 4cia91cq_6
    Snippet: The present review now endeavors to summarize pre-clinical and clinical data of VSV vaccine candidates against emerging infectious diseases. We here specifically focus on those viruses listed by WHO as prioritized pathogens in the R&D Blueprint, and for which VSV vector vaccine candidates have been described: Ebola, Marburg, Lassa, Nipah, Zika, and CCHF viruses as well as MERS-and SARS-coronaviruses. We place a particular emphasis on the Ebola va.....
    Document: The present review now endeavors to summarize pre-clinical and clinical data of VSV vaccine candidates against emerging infectious diseases. We here specifically focus on those viruses listed by WHO as prioritized pathogens in the R&D Blueprint, and for which VSV vector vaccine candidates have been described: Ebola, Marburg, Lassa, Nipah, Zika, and CCHF viruses as well as MERS-and SARS-coronaviruses. We place a particular emphasis on the Ebola vaccine candidate VSV-EBOV, as this vaccine is currently the most advanced candidate of the rVSV platform and the only one that has entered human clinical trials besides an rVSV-vectored HIV vaccine candidate 19 and an oncolytic vaccine (NCT02923466, both in phase I).

    Search related documents:
    Co phrase search for related documents